pyctx.com | ACN 098 391 961 1 31 August 2026 POLYCYSTIC KIDNEY DISEASE – PRESENTATION OF CLINICAL SAFETY DATA • PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available • The Company is...
PKD - Presentation of Clinical Safety Data
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- 2026 Corporate Governance Statement
- Appendix 4G
- 2026 Annual Report to Shareholders
- Appendix 4E
- Notification regarding unquoted securities - PYC
Later from PYC Therapeutics
- Ceasing to be a substantial holder
- ADOA Program - Data Presentation
- Investor Webinar Presentation Q3 2026
- S&P DJI Announces September 2026 Quarterly Rebalance
- PKD - First Patient Dosed in OLE Study
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics